Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer

Cancer Biology and Therapy

Volumn 16, Issue 2, 2015, Pages 253-260

  Mashiko, Satsuki ^a   Kitatani, Kazuyuki ^a,b   Toyoshima, Masafumi ^a   Ichimura, Atsuhiko ^a   Dan, Takashi ^a   Usui, Toshinori ^a,b   Ishibashi, Masumi ^a   Shigeta, Shogo ^c   Nagase, Satoru ^a   Miyata, Toshio ^a   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

Cancer therapeutics; Clear cell carcinoma of the ovary; Ovarian cancer; Plasminogen activator inhibitor 1; Plasminogen activator inhibitor 1 inhibitor; TM5275

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL INTERFERING RNA; TM 5275; UNCLASSIFIED DRUG; 4 AMINOBENZOIC ACID DERIVATIVE; 5-CHLORO-2-(((2-(4-(DIPHENYLMETHYL)PIPERAZIN-1-YL)-2-OXOETHOXY)ACETYL)AMINO)BENZOATE; PIPERAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PROTEIN EXPRESSION; UPREGULATION; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IC50; IMMUNOHISTOCHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PARA-AMINOBENZOATES; PIPERAZINES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN INACTIVATORS; PROGNOSIS; RNA, MESSENGER; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84924551759     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2014.1001271     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138
2. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792-801; PMID:10853003; http://dx.doi.org/10.1056/NEJM200006153422419
3. Schuliga M, Westall G, Xia Y, Stewart AG. The plasminogen activation system: new targets in lung inflammation and remodeling. Curr Opin Pharmacol 2013; 13:386-93; PMID:23735578; http://dx.doi.org/10.1016/j.coph.2013.05.014
4. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg 1997; 84:1651-64; PMID:9448610; http://dx.doi.org/10.1002/bjs.1800841206
5. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002; 26:767-71; PMID:11965442; http://dx.doi.org/10.1007/s00268-002-4050-8
6. Offersen BV, Alsner J, Ege Olsen K, Riisbro R, Brunner N, Sorensen FB, Sorensen BS, Schlemmer BO, Overgaard J. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008; 47:618-32; PMID:18465330; http://dx.doi.org/10.1080/02841860801958295
7. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87:751-6; PMID:7563153; http://dx.doi.org/10.1093/jnci/87.10.751
8. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Hofler H, Janicke F, Graeff H, Schmitt M. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999; 54:147-57; PMID:10424405; http://dx.doi.org/10.1023/A:1006118828278
9. Zekanowska E, Cieslinski K, Rosc D. [Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer]. Pneumonol Alergol Pol 2004; 72:409-14; PMID:16021996
10. Zubac DP, Wentzel-Larsen T, Seidal T, Bostad L. Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. BMC Urol 2010; 10:20; PMID:21129210; http://dx.doi.org/10.1186/1471-2490-10-20
11. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998; 79:449-54; PMID:9761111; http://dx.doi.org/10.1002/(SICI)1097-0215(19981023)79:5%3c449::AID-IJC1%3e3.0.CO;2-0
12. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999; 79:1746-51; PMID:10206287; http://dx.doi.org/10.1038/sj.bjc.6690278
13. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 2012; 31:4139-49; PMID:22158046; http://dx.doi.org/10.1038/onc.2011.572
14. Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost 2008; 100:1029-36; PMID:19132226
15. Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001; 152:741-52; PMID:11266465; http://dx.doi.org/10.1083/jcb.152.4.741
16. Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst 2012; 104:1470-84; PMID:22984202; http://dx.doi.org/10.1093/jnci/djs377
17. Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C, Miyata T. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab 2010; 30:904-12; PMID:20087372; http://dx.doi.org/10.1038/jcbfm.2009.272
18. Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, Kiyomoto H, Ishii N, Okada K, Matsuo O, et al. A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration. Arterioscler Thromb Vasc Biol 2013; 33:935-42; PMID:23471233; http://dx.doi.org/10.1161/ATVBAHA.113.301224
19. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14:5198-208; PMID:18698038; http://dx.doi.org/10.1158/1078-0432.CCR-08-0196
20. Wu K, Urano T, Ihara H, Takada Y, Fujie M, Shikimori M, Hashimoto K, Takada A. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood 1995; 86:1056-61; PMID:7620159
21. DiPaola RS. To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res 2002; 8:3512-9
22. Clin Cancer Res 2002; 8:3311-4; PMID:12429616
23. Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, Martial JA, DeClerck YA. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008; 14:324-34; PMID:18835034; http://dx.doi.org/10.1016/j.ccr.2008.08.012
24. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-89; PMID:9390557; http://dx.doi.org/10.1016/S0092-8674(00)80434-1
25. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2000; 2:156-62; PMID:10707086; http://dx.doi.org/10.1038/35004029
26. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998; 79:449-54; PMID:9761111; http://dx.doi.org/10.1002/(SICI)1097-0215(19981023)79:5%3c449::AID-IJC1% 3e3.0.CO;2-0
27. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999; 79:1746-51; PMID:10206287; http://dx.doi.org/10.1038/sj.bjc.6690278
28. Borgfeldt C, Bendahl P-O, Fernö M, Casslén B. High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer. Gynecol Oncol 2003; 91:112-7; PMID:14529669; http://dx.doi.org/10.1016/S0090-8258(03)00493-1
29. de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, Bolt-De Vries J, Benraad TJ, et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 1999; 80:286-94; PMID:10390010; http://dx.doi.org/10.1038/sj.bjc.6690353
30. Raigoso P, Junco A, Andicoechea A, Gonzalez A, Garcia-Muniz JL, Allende MT, Garcia-Moran M, Vizoso F. Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. Int J Biol Markers 2000; 15:44-50; PMID:10763140
31. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34:122-36; PMID:18162327; http://dx.doi.org/10.1016/j.ctrv.2007.10.005
32. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57:25-40; PMID:10949579; http://dx.doi.org/10.1007/s000180050497
33. Zhang W, Ling D, Tan J, Zhang J, Li L. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance. Oncol Rep 2013; 29:637-45; PMID:23174953
34. DiPaola RS. To arrest or not to G(2)-MCell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res 2002; 8:3512-9
35. Clin Cancer Res 2002; 8:3311-4; PMID:12429616
36. Boe AE, Eren M, Murphy SB, Kamide CE, Ichimura A, Terry D, McAnally D, Smith LH, Miyata T, Vaughan DE. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nomega-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation 2013; 128:2318-24; PMID:24092817; http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003192
37. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107:I17-21; PMID:12814981
38. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351:1077-80; PMID:9660575; http://dx.doi.org/10.1016/S0140-6736(97)10018-6
39. Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434:396-400; PMID:15772665; http://dx.doi.org/10.1038/nature03357
40. Rickles FR. Cancer and thrombosis in women - molecular mechanisms. Thromb Res 2009; 123(Suppl 2):S16-20; PMID:19217469; http://dx.doi.org/10.1016/S0049-3848(09)70004-0
41. Duska LR, Garrett L, Henretta M, Ferriss JS, Lee L, Horowitz N. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol 2010; 116:374-7; PMID:19922988; http://dx.doi.org/10.1016/j.ygyno.2009.10.069
42. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Gene amplification and protein overexpression of MET are common events in ovarian clearcell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 2011; 24:1146-55; PMID:21478826; http://dx.doi.org/10.1038/modpathol.2011.70
43. Yamashita Y, Akatsuka S, Shinjo K, Yatabe Y, Kobayashi H, Seko H, Kajiyama H, Kikkawa F, Takahashi T, Toyokuni S. Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. PLoS One 2013; 8:e57724; PMID:23469222; http://dx.doi.org/10.1371/journal.pone.0057724
44. Liu JJ, Wang W, Dicker DT, El-Deiry WS. Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther 2005; 4:885-92; PMID:16177559; http://dx.doi.org/10.4161/cbt.4.8.2133
45. Kitatani K, Idkowiak-Baldys J, Bielawski J, Taha TA, Jenkins RW, Senkal CE, Ogretmen B, Obeid LM, Hannun YA. Protein kinase C-induced activation of a ceramide/protein phosphatase 1 pathway leading to dephosphorylation of p38 MAPK. J Biol Chem 2006; 281:36793-802; PMID:17030510; http://dx.doi.org/10.1074/jbc.M608137200